NEW YORK (GenomeWeb News) – Rosetta Genomics, a developer of microRNA-based diagnostics and therapeutics based in Rehovot, Israel, has filed papers with the US Securities and Exchange Commission for an initial public offering.
 
According to the SEC filing, dated Sept. 1, the privately held firm plans to sell 3 million shares at $11 to $13 per share, for a maximum offering price of $44.85 million.
 
The company said it has applied to list its shares on the Nasdaq Global Market under the symbol “ROSG.”

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.

Retraction Watch's Ivan Oransky and Adam Marcus report that Harvard Medical School and Brigham and Women's Hospital have recommended that more than 30 papers from a former researcher be retracted.

Thomas Steitz, who won the 2009 chemistry Nobel Prize for his ribosome work, has died, the Washington Post reports.

In PLOS this week: mechanisms for genes implicated in coronary artery disease, rumen microbes and host genetics influence cow methane production, and more.

Nov
05
Sponsored by
Sophia Genetics

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.